In a conference call on June 9th, Advanced Cell Technology reiterated its plans to up-list to Nasdaq, reverse-split, and achieve a large capital raise by the end of the year. This came as a relief to investors and shareholders alike, as shown by the daily share volume in the company.
Advanced Cell Technology, Inc., a biotechnology company, develops and commercializes human pluripotent stem cell technology in the field of regenerative medicine in the United States. The company is conducting various clinical trials for treating dry age-related macular degeneration and ocular therapies; and has a preclinical development pipeline focused on products for autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company's intellectual property portfolio also comprise cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of March 27, 2014, it had 46 issued patents and 178 pending patent applications for the development of intellectual property portfolio.
ACTC closed the day at $.0526, 5.2% higher than its previous close of $.05.